Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well saracatinib works in treating patients with locally
advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.